Popular Keywords
- About Us
-
Research Report
Research Directory
Semiconductors
LED
Consumer Electronics
Emerging Technologies
- Selected Topics
- Membership
- Price Trends
- Press Center
- News
- Events
WitsView, a division of TrendForce, reports shipments of LCD TV sets for the first quarter of 2017 came to 44.05 million units, a decrease of 31% from the prior quarter and a year-on-year decline of 8.4%. Poor sales results in China during the Chinese New Year holiday period was a major factor behind the year-on-year shipment drop.
Market intelligence firm TrendForce reports global tablet shipments for the first quarter of 2017 totaled 31.95 million units, representing a steep drop of 34.5% compared with the prior quarter and a year-on-year decline of 9.3%. The shipment slump was attributed to the effect of the traditional slow season and the general decline in tablet market demand.
The sharp upswing in prices of mobile DRAM products is expected to hold back the growth of average per device memory content for smartphones this year, says the market intelligence firm TrendForce. Furthermore, TrendForce has lowered the estimated average memory content of smartphones for 2017, from 3.7GB to 3.2GB. The revised average memory content figure represents an increase of 33.4% compared with the 2016 figure.
Among the possible new technologies to be incorporated in this year’s refresh of the iPhone series, 3D sensing has generated a lot of interests in terms of applications. A 3D sensing solution requires an RGB camera module an infrared (IR) sensor module that uses VCSEL (vertical-cavity surface-emitting laser) as a light source. With more high-end smartphones adopt 3D sensing, TrendForce estimates that the worldwide market scale of IR sensor modules for mobile devices will reach US$145 million in 2017.
The global market for breast cancer drugs is growing steadily due to rising patient population, introduction of new drugs and sales growth of Perjeta and Kadcyla. The latest biotechnology market report from TrendForce states that the global market scale of breast cancer drugs reached US$11.97 billion in 2016 and is forecast to expand at a CAGR of 9.3% to US$22.35 billion in 2023.